FTC, HHS examining cause of generic drug shortages

FTC, HHS examining cause of generic drug shortages

A variety of generic pills and capsules.  Nenov | Moment | Getty Images The Federal Trade Commission on Wednesday said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account for the majority of Americans’ prescriptions. The move follows an … Read more

Medicare drug price negotiations: Judge tosses PhRMA lawsuit

Medicare drug price negotiations: Judge tosses PhRMA lawsuit

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday dismissed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations that challenged … Read more

Biogen (BIIB) earnings Q4 2023

Biogen (BIIB) earnings Q4 2023

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a … Read more

Novo Nordisk, Eli Lilly are tackling supply issues

Novo Nordisk, Eli Lilly are tackling supply issues

Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments.  The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said … Read more

Wall Street gives Eli Lilly, GE Healthcare well-deserved price target bumps

Wall Street gives Eli Lilly, GE Healthcare well-deserved price target bumps

Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. Analysts at four equity research firms boosted their price targets for GE Healthcare since the maker of MRI machines and other medical equipment on Tuesday delivered … Read more

Merck, J&J, Bristol Myers Squibb CEOs face Senate drug price hearing

Merck, J&J, Bristol Myers Squibb CEOs face Senate drug price hearing

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024. Bill Clark | Cq-roll Call, Inc. | Getty Images Senators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on … Read more

CVS Heath (CVS) Q4 2023 earnings

CVS Heath (CVS) Q4 2023 earnings

A CVS location in New York, US, on Thursday, Feb. 9, 2023. Stephanie Keith | Bloomberg | Getty Images CVS Health on Wednesday reported fourth-quarter revenue and adjusted earnings that topped expectations, but the company cut its full-year profit outlook, citing higher medical costs that are dogging the broader insurance industry. The company lowered its … Read more

Why Wall Street analysts think Big Tech stocks will take a breather

Why Wall Street analysts think Big Tech stocks will take a breather

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks were mixed Tuesday, on a muted performance from Big Tech. Citigroup strategists warned that tech stocks may stall out after monstrous gains. “The large consensus positioning is … Read more

Eli Lilly weight loss drug may treat fatty liver disease

Eli Lilly weight loss drug may treat fatty liver disease

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan McDermid | Reuters Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial.  The initial study … Read more

Eli Lilly (LLY) earnings Q4 2023

Eli Lilly (LLY) earnings Q4 2023

Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020.  Mike Blake | Reuters Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. … Read more